cas 23877-12-5|| where to buy tert-Butyl 2-bromoisobutyrate

Nom du produit:tert-Butyl 2-bromoisobutyrate

IUPAC Name:tert-butyl 2-bromo-2-methylpropanoate

Unité d'emballage	Stock disponible	Prix($)
CM361119-500g	in stock	Ǹƴ
CM361119-1000g	in stock	Žǟř

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 23877-12-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:23877-12-5; Formule moléculaire:C8H15BrO2; Point de fusion:-; Code SMILES:CC(C)(Br)C(OC(C)(C)C)=O; Densité:

: Numéro de catalogue:CM361119; Poids moléculaire:223.11; Point d'ébullition:; N° Mdl:MFCD00051908; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.